Compare Extra Space Storage, Inc. (EXR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Merck & Co., Inc. — how do they compare? Extra Space Storage, Inc. trades at $134.65 (market cap $28.12B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 12.5× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.87%). Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Merck & Co., Inc. for 98 Days on average.
| EXR | MRK | |
|---|---|---|
Market Cap | $28.12B | $351.28B |
Volume | 2,595,579 | 7,969,665 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $156.43 |
52-Week Low | $126.67 | $82.49 |
Typical Hold Time | 109 Days | 98 Days |
Enterprise Value | $41.84B | $398.04B |
Dividend Yield | 4.87% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $133.12, up 1.08% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38 billion in 2025, and net income margin remains healthy at 27.79%. Analyst consensus is evenly split between Buy and Hold, with a price target of $158.33 implying upside potential. Recent news highlights leadership transition and institutional buying interest.
EXR presents a balanced risk-reward profile. Upside is supported by steady demand, dividend payments, and analyst targets, but risks include high leverage, interest rate sensitivity, and a bearish technical trend. The stock's valuation multiples are elevated, requiring sustained earnings growth to justify current levels. Investors should weigh solid fundamentals against macroeconomic headwinds affecting REITs.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
